Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    21969503 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
Conditions: Vaginal Cancer;   Cervical Cancer;   Anal Cancer;   Penile Cancer;   Oropharyngeal Cancer
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: E6 TCR;   Drug: Aldesleukin
2 Completed Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Conditions: Cervical Cancer;   Oropharyngeal Cancer;   Vaginal Cancer;   Anal Cancer;   Penile Cancer
Interventions: Drug: Fludarabine;   Drug: Cycolphosphamide;   Biological: Young TIL;   Drug: Aldesleukin
3 Recruiting Quarterback 2 - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer
Condition: Locally Advanced HPV Positive Oropharynx Cancer
Interventions: Radiation: PTV56;   Radiation: PTV50.4
4 Recruiting The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
Condition: Squamous Cell Carcinomas
Interventions: Radiation: Reduced Dose Radiation;   Radiation: Standard Dose Radiation

Study has passed its completion date and status has not been verified in more than two years.